Fortress Biotech (FBIO)
(Delayed Data from NSDQ)
$1.84 USD
0.00 (0.00%)
Updated Jun 5, 2024 04:00 PM ET
After-Market: $1.86 +0.02 (1.09%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Income Statements
Fiscal Year end for Fortress Biotech, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 85 | 76 | 69 | 46 | 37 |
Cost Of Goods | 27 | 31 | 32 | 15 | 11 |
Gross Profit | 58 | 45 | 37 | 31 | 26 |
Selling & Adminstrative & Depr. & Amort Expenses | 200 | 249 | 225 | 125 | 137 |
Income After Depreciation & Amortization | -142 | -204 | -189 | -94 | -111 |
Non-Operating Income | 4 | 4 | 40 | 7 | 21 |
Interest Expense | 15 | 14 | 15 | 15 | 12 |
Pretax Income | -154 | -213 | -164 | -103 | -102 |
Income Taxes | 1 | 0 | 0 | 0 | 0 |
Minority Interest | -94 | -127 | -100 | -56 | -62 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -154 | -214 | -165 | -103 | -102 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -61 | -87 | -65 | -47 | -40 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -131 | -192 | -178 | -83 | -103 |
Depreciation & Amortization (Cash Flow) | 11 | 11 | 11 | 11 | 8 |
Income After Depreciation & Amortization | -142 | -204 | -189 | -94 | -111 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 8.11 | 5.93 | 5.45 | 4.80 | 3.65 |
Diluted EPS Before Non-Recurring Items | -8.47 | -14.54 | -11.84 | -9.75 | -10.95 |
Diluted Net EPS (GAAP) | -8.47 | -14.54 | -11.84 | -9.75 | -10.94 |
Fiscal Year end for Fortress Biotech, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | 13.03 | 19.95 | 34.75 | 17.39 | 12.43 |
Cost Of Goods | 6.82 | 6.01 | 6.43 | 7.77 | 6.45 |
Gross Profit | 6.21 | 13.93 | 28.32 | 9.62 | 5.98 |
SG&A, R&D, and Dept/Amort Expenses | 42.78 | 36.69 | 42.08 | 59.72 | 64.85 |
Income After SG&A, R&D, and Dept/Amort Expenses | -36.57 | -22.76 | -13.76 | -50.10 | -58.87 |
Non-Operating Income | 0.15 | -6.93 | 5.71 | -2.77 | 8.02 |
Interest Expense | 2.60 | 2.06 | 2.53 | 6.43 | 4.30 |
Pretax Income | -39.02 | -28.60 | -10.58 | -59.30 | -55.15 |
Income Taxes | 0.00 | 0.38 | 0.14 | 0.00 | 0.00 |
Minority Interest | -23.61 | -19.70 | -5.68 | -34.53 | -33.61 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -39.02 | -28.98 | -10.72 | -59.30 | -55.15 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -15.42 | -9.28 | -5.05 | -24.78 | -21.54 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | 17.15 | 8.11 | 7.50 | 7.38 | 6.80 |
Diluted EPS Before Non-Recurring Items | -1.03 | -0.53 | -0.94 | -3.60 | -3.15 |
Diluted Net EPS (GAAP) | -1.03 | -0.78 | -0.94 | -3.60 | -3.15 |